Kintai Therapeutics, Paul-Peter Tak
Flagship Pioneering announced the launch of a new biotech company and the man who will act as the CEO, Paul-Peter Tak.
Tak transitioned into the role after holding a venture partner position at Flagship for seven months before being appointed CEO of the biotech.
Tak previously held the position of SVP and chief immunology officer at GSK, working at the company for seven year, and also had experience leading Tempero Pharmaceutical, a biotech spin-off from GSK, for four years.
Flagship’s latest project will focus on the gut and its immune cells to generate ‘a new class of precision enteric medicine’. Kintai will apply its PEM discovery and development platform to therapeutics that target the enteric signalling system.
Tak said, "I believe Kintai is poised to transform gastrointestinal biology and is particularly well positioned to make major therapeutic advancements in the field by leveraging a prolific and disruptive discovery and development strategy.”
“I am proud of the team, which has already harnessed new insights into more than 10 drug programs," he continued.
The drug programs are spread across autoimmune, metabolic, neurologic, and cancer indications.
